CLINICOPATHOLOGICAL STUDY OF OVARIAN NEOPLASMS – AN INSTITUTIONAL PERSPECTIVE

VASUNDARA GARDAS; PRASANTHI CHERUKURI; SUMERA SALOMI

doi:10.22159/ajpcr.2022.v15i1.43429

Authors

VASUNDARA GARDAS Department of Pathology, GITAM Institute of Medical Sciences and Research, GITAM Deemed to be University, Visakhapatnam, Andhra Pradesh, India.
PRASANTHI CHERUKURI Department of Pathology, GITAM Institute of Medical Sciences and Research, GITAM Deemed to be University, Visakhapatnam, Andhra Pradesh, India.
SUMERA SALOMI Department of Physiology, GITAM Institute of Medical Sciences and Research, GITAM Deemed to be University, Visakhapatnam, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i1.43429

Keywords:

Ovarian neoplasm, Benign borderline, Malignant

Abstract

Objective: The objective of the study was to know the frequency and histomorphological patterns of ovarian neoplasms concerning age.

Methods: A 2-year retrospective study was done in the pathology department, GITAM Institute of Medical Sciences and Research. Data were retrieved from laboratory records, H & E slides of ovarian biopsies of diagnosed neoplasms were screened.

Results: During the study period, 70 ovarian neoplasms were reported. Ovarian tumors were categorized according to the WHO classification. In this study surface, epithelial tumors were most common at 87.14% followed by germ cell tumors at 11.42% and sex cord-stromal tumors at 1.42%. Serous cystadenoma was the most common benign surface epithelial tumor.

Conclusion: Histopathology is the gold standard for diagnosing ovarian neoplasms. Newer diagnostic techniques such as immunohistochemistry and morphometric analysis help decide management and prognosis.

Downloads

Download data is not yet available.

References

Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer 2006;6:603-12.

Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and non-carriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-40.

Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: Have they different risk factors? Gynecol Oncol 2005;96:520-30.

Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement therapy and ovarian cancer risk: A meta-analysis. Gynecol Oncol 2008;108:641-51.

Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS. Ovarian cancer: Can we make the clinical diagnosis earlier. Cancer 2005;104:1398-407.

Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000;89:2068-75.

Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 1988;62:2212-22.

Akeson M, Jakobsen AM, Zetterqvist BM. A population-based 5-year cohort study including all epithelial ovarian cancer cases in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer 2009;19:116-23.

Barlin JN, Jelinic P, Olvera N, Bogomolniy F, Bisogna M, Dao F, et al. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol Oncol 2013;128:512-7.

Suidan RS, Ramirez PT, Sarasohn DM, Teicher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluates the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 2014;134:455-61.

Kurman RJ, Ellenson LH, Ronnett BM. Blaustein’s Pathology of the Female Genital Tract. 6th ed. USA: Springer; 2011.

Ranjana H, Sadhna S, Ekta P. Histopathological spectrum of ovarian tumors-a two-year retrospective study. Indian J Pathol Oncol 2017;4:450-3.

Prakash A, Chinthakindi S, Duraiswami R, Indira V. Histopathological study of ovarian lesions in a tertiary care center in Hyderabad, India: A retrospective five-year study. Int J Adv Med 2017;4:745-9.

Vinitha S, Shreya H, Zulfikar A, Umaru N. Histopathological study of malignant soft tissue tumors. J Evol Med Den Sci 2015;14:3320-8.

Garg N, Anand AS, Annigeri C. Study of histomorphological spectrum of ovarian tumors. Int J Med Health Res 2017;3:12-20.

Hardik HM, Maru A, Lakum N, Ashok A, Naresh T, Jayesh J. Relative frequency and histopathological pattern of ovarian masses. Int J Med Sci Public Health 2014;3:81-4.

Pilli GS, Suneeta KP, Dhaded AV, Yenni VV. Ovarian tumors: A study of 282 cases. J Indian Med Assoc 2002;100:420, 423-4, 447.

Manoja V, Pramod M, Jyothi V, Chandrashekar KP. Clinicopathological study of ovarian tumors: A 2-year study. Int J Sci Stud 2017;5:300-5.

Mankar DV, Jain GK. Histopathological profile of ovarian tumors: A twelve-year institutional experience. Muller J Med Sci Res 2015;6:107-11.

Garg N, Anand AS, Annigeri C. Study of the histomorphological spectrum of ovarian tumors. Int J Med Health Res 2017;3:12-20.

Kanpurwala SH, Chavan SM, Agrawal S. A study of clinicomorphological profile of ovarian tumours in Western India. J Med Sci Clin Res 2016;4:15040-7.

Modepalli N, Venugopal SB. Clinicopathological study of surface epithelial tumours of the ovary: An institutional study. J Clin Diagn Res 2016;10:EC01-4.

Patil RK, Bhandari BJ, Kittur SK, Haravi RM, Aruna S, Jadhav MN. Histomorphological study of ovarian tumours at a tertiary care centre. Ann Pathol Lab Med 2017;4:638-45.

Sanjeev N, Anjali S, Shrikant N, Rahul K. Spectrum of ovarian tumours-a five year study. J Pathol Nepal 2017;7:1180-3.

Malli M, Vyas B, Gupta S, Desai H. A histological study of ovarian tumours in different age groups. Int J Med Sci Public Health 2014;3:338-41.